These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26748052)

  • 1. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
    Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
    Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
    Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL
    J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
    Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
    Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain.
    Felder CC; Schober DA; Tu Y; Quets A; Xiao H; Watt M; Siuda E; Nisenbaum E; Xiang C; Heinz B; Prieto L; McKinzie DL; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):190-197. PubMed ID: 28138041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects.
    Witkin JM; Monn JA; Li J; Johnson B; McKinzie DL; Wang XS; Heinz BA; Li R; Ornstein PL; Smith SC; Mitch CH; Calligaro DO; Swanson S; Allen D; Phillips K; Gilmour G
    Pharmacol Biochem Behav; 2017 Apr; 155():43-55. PubMed ID: 28285123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells.
    Johnson BG; Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    Neuropharmacology; 1999 Oct; 38(10):1519-29. PubMed ID: 10530814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
    Kingston AE; Ornstein PL; Wright RA; Johnson BG; Mayne NG; Burnett JP; Belagaje R; Wu S; Schoepp DD
    Neuropharmacology; 1998; 37(1):1-12. PubMed ID: 9680254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist.
    Hanna L; Ceolin L; Lucas S; Monn J; Johnson B; Collingridge G; Bortolotto Z; Lodge D
    Neuropharmacology; 2013 Mar; 66():114-21. PubMed ID: 22445601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.
    Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    J Pharmacol Exp Ther; 2001 Aug; 298(2):453-60. PubMed ID: 11454905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
    Nakazato A; Sakagami K; Yasuhara A; Ohta H; Yoshikawa R; Itoh M; Nakamura M; Chaki S
    J Med Chem; 2004 Aug; 47(18):4570-87. PubMed ID: 15317467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective activation of either mGlu2 or mGlu3 receptors can induce LTD in the amygdala.
    Lucas SJ; Bortolotto ZA; Collingridge GL; Lodge D
    Neuropharmacology; 2013 Mar; 66():196-201. PubMed ID: 22531751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.
    Molinaro G; Traficante A; Riozzi B; Di Menna L; Curto M; Pallottino S; Nicoletti F; Bruno V; Battaglia G
    Mol Pharmacol; 2009 Aug; 76(2):379-87. PubMed ID: 19439499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.
    Dominguez C; Prieto L; Valli MJ; Massey SM; Bures M; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD; Monn JA
    J Med Chem; 2005 May; 48(10):3605-12. PubMed ID: 15887967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.
    Monn JA; Valli MJ; Massey SM; Hao J; Reinhard MR; Bures MG; Heinz BA; Wang X; Carter JH; Getman BG; Stephenson GA; Herin M; Catlow JT; Swanson S; Johnson BG; McKinzie DL; Henry SS
    J Med Chem; 2013 Jun; 56(11):4442-55. PubMed ID: 23675965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding.
    Richards G; Messer J; Malherbe P; Pink R; Brockhaus M; Stadler H; Wichmann J; Schaffhauser H; Mutel V
    J Comp Neurol; 2005 Jun; 487(1):15-27. PubMed ID: 15861463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.